From Science Daily:
Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only about three in ten such patients undergo the procedure, according to a new study by researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital. The study, published by the Journal of Clinical Oncology, also found that patients are more likely to receive the surgery – known as cytoreductive nephrectomy – if they are treated at an academic medical center, have a smaller tumor, are young, and privately insured.
